Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-195263 in meibomian gland dysfunction
NCT01633788Phase 2Completed
- Sponsor
- Allergan
- Start
- Aug 2012
- Primary completion
- Feb 2015
- Countries
- 1
01
Overview
A Phase 2 trial of AGN-195263 in meibomian gland dysfunction (MGD), sponsored by Allergan. Started Aug 2012; status: completed.
02
Drugs
AGN-195263
03
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT01633788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01633788.